Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 15/20 | 0.71 |
| ▸ | RARB | P10826 | 15/20 | 0.71 |
| ▸ | RARG | P13631 | 14/20 | 0.71 |
| ▸ | RXRA | P19793 | 1/20 | 0.71 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.45 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234039 | 1.00 | RARA (0.71) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL4510443 | 0.92 | RARB (0.60) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL4510438 | 0.92 | RARB (0.60) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL27509813 | 0.88 | RARB (0.56) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8327936 | 0.85 | RARB (0.54) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8327932 | 0.85 | RARB (0.54) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6293847 | 0.85 | RARA (0.59) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6293846 | 0.85 | RARA (0.59) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL27464662 | 0.85 | RARA (0.52) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL29613352 | 0.83 | RARA (1.00) | RARARARBRARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931786-B1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | ALLERGAN INC (US) | 2003-08-06 | — | — | EP | claimed |
| US-20020156054-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | ALLERGAN, INC. | 2002-10-24 | — | — | US | claimed |
| US-6008204-A | ANTIDOTES FOR PREVENTING CERTAIN UNDESIRED SIDE EFFECTS OF RETINOIDS | ALLERGAN SALES, INC. (US) | 1999-12-28 | — | — | US | claimed |
| EP-0931786-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Vision Pharmaceuticals L.P. (US) | 1999-07-28 | — | — | EP | claimed |
| US-20230042181-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-02-09 | — | — | US | disclosed |
| US-11447831-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210285059-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | SYROS PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3277272-B1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-AGONISTS | SYROS PHARMACEUTICALS INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11053552-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists | SYROS PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200392583-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2020-12-17 | — | — | US | disclosed |
| US-10697025-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190249259-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-08-15 | — | — | US | disclosed |
| US-6218128-B1 | DRUG SCREENING FOR INVERSE AGONIST BY MONITORING BINDING OF TWO POLYPEPTIDES HAVING SPECIFIC DOMAINS IN PRESENCE OF TEST COMPOUND | ALLERGAN SALES, INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1042313-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | Allergan Sales, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6090810-A | SIDE EFFECT REDUCTION | ALLERGAN SALES, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0991636-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | Allergan Sales, Inc. (US) | 2000-04-12 | — | — | EP | disclosed |
| US-6008204-A | ANTIDOTES FOR PREVENTING CERTAIN UNDESIRED SIDE EFFECTS OF RETINOIDS | ALLERGAN SALES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0931786-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Vision Pharmaceuticals L.P. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999033821-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998058922-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | ALLERGAN SALES, INC. (US) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210285059-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-10697025-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-20200392583-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-20190249259-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-11053552-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists | RARA, RARB, RARG | RARA 1/4885RARB 2/4885RARG 3/4885 |
| US-20020156054-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | RXRA, RARA, RXRG | RARA 2/4885RARB 7/4885RARG 4/4885 |
| US-11447831-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-20230042181-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.